Jaguar Health Inc.

11.06
3.00 (37.22%)
At close: Apr 25, 2025, 3:59 PM
10.89
-1.51%
After-hours: Apr 25, 2025, 05:58 PM EDT

Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea.

The company operates through two segments, Human Health and Animal Health.

It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.

In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs.

Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Jaguar Health Inc.
Jaguar Health Inc. logo
Country United States
IPO Date May 12, 2015
Industry Biotechnology
Sector Healthcare
Employees 49
CEO Lisa A. Conte

Contact Details

Address:
200 Pine Street
San Francisco, California
United States
Website https://jaguar.health

Stock Details

Ticker Symbol JAGX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001585608
CUSIP Number 47010C805
ISIN Number US47010C8055
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Lisa A. Conte Founder, Chief Executive Officer, President & Director
Carol R. Lizak M.B.A. Chief Financial Officer & Chief Accounting Officer
Catherine Miller Collis Senior Vice President of Growth Strategy
David Sesin Ph.D. Chief Manufacturing Officer
Dr. Karen J. Brunke Ph.D. Executive Vice President of Corporate & Business Development
Dr. Massimo Radaelli M.B.A., Ph.D. President of Jaguar International
Dr. Pravin R. Chaturvedi Ph.D. Chief Scientific Officer & Chair of Scientific Advisory Board
Dr. Steven R. King Ph.D. Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
Ian H. Wendt M.B.A. Chief Commercial Officer
Peter Hodge Senior Director of Investor Relations, Business Development & Special Events

Latest SEC Filings

Date Type Title
Apr 21, 2025 8-K Current Report
Apr 15, 2025 S-8 Filing
Apr 15, 2025 S-3 Filing
Apr 15, 2025 10-K/A [Amend] Annual Report
Apr 04, 2025 8-K Current Report
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing